Bavarian Nordic: "We are ready to buy more vaccines"

In recent years, the Danish drugmaker has acquired vaccines for both commercialization and development -- this could very well happen again, according to CFO Henrik Juuel.

Photo: Pool/Reuters/Ritzau Scanpix

As orders keep coming for Bavarian Nordic’s monkeypox vaccine, the Danish drugmaker has restated its ambition to become one of the world’s biggest vaccine companies.

To reach this goal, however, it could prove necessary to expand the portfolio by other means than development, according to Bavarian Nordic Chief Financial Officer Henrik Juuel.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs